Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14894156 | 0.86 | HDAC6 (0.36) | HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL28612600 | 0.81 | KMT2A (0.38) | HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL9171625 | 0.78 | HDAC6 (0.50) | HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL28433286 | 0.77 | HDAC6 (0.41) | HDAC6HDAC1HDAC2DPP4 | |
| SCHEMBL956549 | 0.76 | ALDH1A1 (0.42) | HDAC6HDAC1HDAC2L3MBTL1DPP4 | |
| SCHEMBL2622073 | 0.76 | HDAC6 (0.38) | HDAC6HDAC1HDAC2L3MBTL1DPP4 | |
| SCHEMBL26664948 | 0.76 | L3MBTL1 (0.36) | HDAC6L3MBTL1DPP4 | |
| SCHEMBL17162509 | 0.74 | HDAC6 (0.37) | HDAC6HDAC1HDAC2L3MBTL1DPP4 | |
| SCHEMBL2754735 | 0.74 | HDAC6 (0.37) | HDAC6HDAC1HDAC2L3MBTL1DPP4 | |
| SCHEMBL18756074 | 0.74 | HDAC6 (0.46) | HDAC6HDAC1HDAC2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210252014-A1 | OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS INC (US) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210252014-A1 | OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | HDAC6 886/4885HDAC1 249/4885HDAC2 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.